Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal cell carcinoma with a predominant clear cell component confirmed by histology.~* Advanced disease: metastatic AND, not suitable for resection~* Male or female, aged 18 years or older~* ECOG (Eastern Cooperative Oncology Group) Performance Status of 0 or 1~* Low or intermediate MSKCC (Memorial Sloan Kettering Cancer Center) prognostic risk score,i.e. no more than 2 of the following:~  * Karnofsky performance status (\<80%)~ * Low serum hemoglobin (≤ 13 g/dL for males and ≤ 11.5 g/dL for females)~ * High corrected serum calcium (≥ 10 mg/dL)~* Target and/or non-target lesions according to RECIST 1.1 ( Response Evaluation Criteria in Solid Tumors)~* Expected survival of at least 3 months.~* No prior systemic treatment. But adjuvant treatment is ok if stopped from ≥ 24 months~* Adequate bone marrow function as shown by:~* Adequate liver function as shown by:~* Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN (upper limit of normal)~* Left ventricular ejection fraction ≥55% on gated cardiac blood pool scan, or normal left ventricular function and fractional shortening on echocardiogram (according to institutional limits).~* SBP (systolic blood pressure) ≤140mmHg and DBP (diastolic blood pressure)~  * 90mmHg (it is acceptable to initiate antihypertensive treatment prior to registration to achieve these goals).~* Able to commence treatment within 7 days of registration.~* Willing and able to comply with follow-up and all other protocol requirements.~* Written informed consent~Exclusion Criteria:~* Prior treatment with VEGF-targeting agents or multi-kinase inhibitors or mTOR-targeting agents~* Active central nervous system metastases.~* Other malignancy diagnosed within the last 5 years, except the following if adequately treated: superficial squamous cell carcinoma or basal cell carcinoma of skin, superficial bladder cancer (T1 and G1 or T1 and G2), stage 1 cervical cancer.~* Treatment with an investigational agent in the last 4 w.~* Known to be HIV positive.~* Evidence of chronic hepatitis due to hepatitis B virus (HBV) or hepatitis C virus (HCV)~* Clinically significant heart disease (NYHA Class III or IV)~* History of hypertension requiring hospitalization.~* Other serious illnesses,~* Immunotherapy or chemotherapy in the last 4 w (6 weeks for nitrosoureas)~* Major surgery in the last 4 w, or planned in the next 6 w~* Radiation therapy in the last 2 w, or planned in the next 6 w~* NCI CTCAE (Common Toxicity Criteria for Adverse Effects) version 4.0 grade 3 or worse hemorrhage in last 4 w.~* Any of the following in the last year: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.~* Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.~* Ongoing cardiac dysrhythmias of NCI CTCAE version 4.0 grade ≥2, atrial fibrillation of any grade, or prolongation of the corrected QT interval (QTc) to \>450 msec for males or \>470 msec for females~* Uncontrolled diabetes as defined by fasting serum glucose \>1.5 X ULN.~* Pregnancy,lactation. Inadequate contraception.~* Known allergy or hypersensitivity to everolimus, sunitinib or iodine.~* Medical or psychiatric condition that compromises the patient's ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotational arm (Type: EXPERIMENTAL): Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.
- Sequential arm (Type: ACTIVE_COMPARATOR): The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).